1st Quarter - Amendment

ALSTON & BIRD LLP for TRAVERE THERAPEUTICS

Firm
Client
Income
$60,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 21, 2025 $60,000 Replaced
1st Quarter - Amendment (this page) Mar 3, 2026 $60,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025.

LobbyistCovered position, as disclosed
ZOE ATCHINSON —
JAMES PATRICK PALUSKIEWICZ —
MARK RAYDER —
ROBERT SIGGINS —
MARILYN K YAGER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1968 (119th), H.R. 946 (119th), H.R. 1518 (119th)

Medicare/Medicaid MMM

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation impacting products approved under the Accelerated Approval pathway. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.

LobbyistCovered position, as disclosed
ZOE ATCHINSON —
JAMES PATRICK PALUSKIEWICZ —
MARK RAYDER —
ROBERT SIGGINS —
MARILYN K YAGER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 946 (119th), H.R. 1518 (119th)

Pharmacy PHA

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding orphan drug pricing, value, and reimbursement, relative to the Inflation Reduction Act of 2022 (Pub. L. No. 117-169, 136 Stat. 1818 (2022)). Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025.

LobbyistCovered position, as disclosed
ZOE ATCHINSON —
MARK RAYDER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1968 (119th), H.R. 946 (119th)

Medical/Disease Research/Clinical Labs MED

Legislation regarding clinical research for rare diseases and orphan drug development, and the Accelerated Approval pathway. Support of reauthorization of priority review voucher program.

LobbyistCovered position, as disclosed
ZOE ATCHINSON —
JAMES PATRICK PALUSKIEWICZ —
MARK RAYDER —
ROBERT SIGGINS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit. Legislation to improve education and care pathways for patients with rare kidney disease.

LobbyistCovered position, as disclosed
MARK RAYDER —
ROBERT SIGGINS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1414 (119th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.